Antonio Antela

Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

José A. Pérez‐Molina, Rafael Rubio, Antonio Rivero et al. · The Lancet Infectious Diseases · 2015 · 130 citations · Full text

Hiv/aids Counselling, Treatment And Prevention, Neurovirology +9

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

Anton Pozniak, Martin Markowitz, Anthony Mills et al. · The Lancet Infectious Diseases · 2014 · 98 citations · Full text

Human Retrovirus, Antiviral Drug Development, Clinical Trials +9

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

José A. Pérez‐Molina, Rafael Rubio, Antonio Rivero et al. · Journal of Antimicrobial Chemotherapy · 2016 · 62 citations · Full text

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice

Inés Suárez‐García, Belén Alejos, Víctoria Hernando et al. · Journal of Antimicrobial Chemotherapy · 2023 · 26 citations · Full text

Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study

Lluı́s Castells, Antoni Rimola, Christian Manzardo et al. · Journal of Hepatology · 2014 · 21 citations · Full text

Transplantation, Hepatology, Hepatitis C +14